Our proof of concept, demonstrated through the successful generation of efficacy data for CIDP (SAR445088), showcases the potential of these models in clinical trials.

At NEXI Biotech, we are dedicated to advancing this model for more patients suffering from neurological disease.

Our pioneering research, recognized as contributing to passing of the FDA Modernization Act 2.0, establishes these methodologies as pivotal for future drug discovery endeavors.

This vision represents the frontier of personalized medicine.

NEXI Biotech serves to empower revolutionary in vitro technologies that redefine the future of drug discovery.